Ceplene is a pharmaceutical-grade form of histamine dihydrochloride, which is used for the prevention of relapse in patients diagnosed with acute myeloid leukemia (AML).
Contents |
Ceplene is administered in conjunction with low doses of the immune-activating cytokine interleukin-2 (IL-2) in the post-remission phase of AML, i.e. when patients have completed the initial chemotherapy. Ceplene/IL-2 has been reported to significantly reduce the risk of relapse in AML[1]. The effect is particularly pronounced in patients in their first remission who are below the age of 60[2].
The combination of Ceplene and interleukin-2 was approved for use in AML patients within the European Union in October 2008[3] and will be marketed in the EU by the Swedish pharmaceutical company Meda. Ceplene is also available through a named patient program in several other countries (excluding the US).
Ceplene acts by improving the immune-enhancing properties of IL-2, and laboratory studies have shown that Ceplene/IL-2 can induce immune-mediated killing of leukemic cells[4]. The treatment (in the form of subcutaneous injections) is given in 3-week cycles by the patients at home for 18 months, thus coinciding with the period of highest relapse risk. The side-effects of Ceplene include transient flush and headache, whereas IL-2 may induce low-grade fever and inflammation at the site of injection. Ceplene has been developed by researchers at the University of Gothenburg, Sweden.